---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-039343"
form_type: "8-K/A"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T11:17:02.706193+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Elicio files historical financials of Private Elicio post-merger; Q1 net loss $8.0M, going concern flagged

## Summary
- Private Elicio net loss of $8.0M for Q1 2023; accumulated deficit $115.0M at March 31, 2023.
- Cash and equivalents of $8.6M at March 31, 2023; negative operating cash flow of $8.1M in Q1.
- Auditor's going concern opinion citing losses, negative cash flows, and need for additional financing.
- Merger with Angion closed June 1, 2023; company renamed Elicio Therapeutics, now trading as ELTX.
- Pro forma combined financials filed; no revenue for Private Elicio in the periods presented.

## SEC filing metadata
- accession: 0001140361-23-039343
- form_type: 8-K/A
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000114036123039343/0001140361-23-039343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000114036123039343/brhc20057283_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-039343
- JSON: https://secwatch.observer/filing/0001140361-23-039343.json
- Plain text: https://secwatch.observer/filing/0001140361-23-039343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.